Valued at USD 3.19 billion in 2024, the U.S. neurology clinical trials market is projected to reach USD 3.40 billion in 2025 and USD 6.07 billion by 2034, growing at a CAGR of 6.7% during the forecast period 2025–2034. While federal funding and disease burden anchor demand, technology is changing how trials are designed, staffed, and monitored. This article focuses on AI, data, and outsourcing trends that B2B sponsors and service providers should track in the U.S. neurology clinical trials market.

AI Across the Trial Lifecycle

The report lists several AI impacts on U.S. neurology trials. AI-powered patient recruitment tools improve enrollment efficiency by identifying eligible candidates faster and more accurately through electronic health records and predictive analytics. Machine learning platforms enhance trial design by analyzing historical data to optimize protocols, reduce trial duration, and increase the likelihood of success.

AI in drug discovery and target identification allows biotech and pharma companies to identify promising neurological compounds more rapidly and cost-effectively, and natural language processing streamlines data extraction and analysis from clinical notes, medical literature, and patient-reported outcomes, improving trial monitoring and reporting. The U.S. government, particularly through the National Institutes of Health, provides substantial funding for neurology research, and the BRAIN Initiative and Alzheimer's-focused programs receive billions annually. According to the Alzheimer's Association, 7 million people in the country have Alzheimer's disease.

Browse Insights:

 https://www.polarismarketresearch.com/industry-analysis/us-neurology-clinical-trials-market

Observational Studies and Real-World Data

The observational studies segment is anticipated to register the highest growth rate during the forecast period, driven by increasing demand for real-world evidence in neurology research. These non-interventional studies capture data on patient behavior, treatment impact, and disease progression, which matters because disorders such as Alzheimer's and Parkinson's have long-term, progressive outcomes. Healthcare systems, insurers, and regulatory bodies are pushing for more data beyond traditional trial results, and digital health records and patient registries provide a foundation for conducting observational studies efficiently and at scale. The report segments the market by phase, study design, indication, and value chain, with in-house, CROs, and investigator site and clinical site segments making up the value chain.

CROs Gain Share

The CROs segment is anticipated to register the highest growth rate, driven by rising trial complexity and pressure to reduce costs and timelines. Pharmaceutical and biotech companies increasingly outsource research to specialized CROs. U.S.-based CROs offer deep neurology expertise, regulatory knowledge, and access to vast patient networks, and their ability to manage multi-site trials, navigate FDA requirements, and integrate AI and digital monitoring tools makes them major partners.

Awareness and Recruitment Challenges

Public awareness of neurological conditions is rising in the U.S., driven by education campaigns, nonprofit organizations, and advocacy groups, which fuels patient participation. Even so, limited patient recruitment for rare neurological disorders and complex trial protocols restrains growth. The Alzheimer's disease segment held the largest indication share in 2024, and the phase III segment led by phase. The U.S. Food and Drug Administration supports trials through programs such as Fast Track, Breakthrough Therapy, and Orphan Drug designations, which help speed approval for drugs targeting serious or rare conditions. The U.S. is also home to world-renowned hospitals, research universities, and specialized neurology centers, including the Mayo Clinic, Cleveland Clinic, and Johns Hopkins, and centralized health data and advanced diagnostic tools improve trial accuracy and efficiency.

Key Players and Outlook

Key players u.s. neurology clinical trials include Biogen, Charles River Laboratories, Eisai Co., Ltd., ICON plc, IQVIA, Laboratory Corporation of America Holdings, Medpace Holdings, Inc., Parexel, Pfizer Inc., Syneos Health, and Thermo Fisher Scientific. Strategic collaborations, AI-based tools, and increasing outsourcing define competitive dynamics. In February 2025, Thermo Fisher launched a clinical registry and biorepository for Systemic Lupus Erythematosus through CorEvitas. With a 6.7% CAGR, the market rewards providers that deliver faster, data-driven trial execution. The market is characterized by a highly competitive mix of pharmaceutical firms, biotechnology companies, and specialized CROs.

More Trending Latest Reports By Polaris Market Research:

e-commerce-market

silicon-carbide-market

machine-tools-market

wound-care-market

surfactants-market

gan-gallium-nitride-semiconductor-devices-market

us-biostimulants-market

glioblastoma-multiforme-gbm-treatment-market

industrial-valve-market